Rituximab for follicular lymphoma: maintaining an open mind

Bruce Cheson

New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations of cost, inconvenience, toxic effects, efficacy of retreatment and lack of survival benefit should focus future clinical research on more-effective induction strategies.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.